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INTRODUCTION
Although there has been remarkable progress in the
treatment of Hodgkin’s disease, approximately 10% to 15%
of pediatric patients fail to achieve a complete response (CR)
or subsequently relapse [1,2]. Poor results following salvage
therapy have led to the use of high-dose therapy (HDT) fol-
lowed by autologous hematopoietic cell transplantation
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ABSTRACT
The use of high-dose therapy (HDT) and autologous hematopoietic cell transplantation (AHCT) for children and
adolescents with primary refractory and relapsed Hodgkin’s disease is increasing. The purpose of this retrospective
analysis was to: (1) evaluate the outcome of HDT and AHCT in pediatric patients with Hodgkin’s disease, and
(2) identify factors that predispose patients to the development of transplantation-related complications. We
describe the experiences of 34 pediatric patients from a single institution with primary refractory or relapsed
Hodgkin’s disease. HDT regimens consisted of cyclophosphamide and etoposide combined with either carmustine,
chloroethylcyclohexylnitrosurea, or fractionated total body irradiation. Kaplan-Meier survival predicts that 67%
(95% confidence interval [CI] 47%-87%) of patients will be alive and disease-free at 5 years. Nine patients had dis-
ease recurrence, of whom 5 relapsed after 1 year (1.5-6.3 years). Five patients succumbed to treatment-related tox-
icities, of whom 4 died of pulmonary failure. Fifteen patients (44%) developed post-AHCT idiopathic diffuse lung
injury syndrome: acute alveolitis (n = 2); diffuse alveolar hemorrhage (n = 2); acute respiratory distress syndrome
(n = 2); delayed interstitial pneumonitis (n = 8); and bronchiolitis obliterans (n = 1). The following factors did not
predict for the development of a diffuse lung injury syndrome in univariate analysis: prior treatment with
bleomycin, pre-HDT pulmonary function tests, and prior thoracic irradiation. Of the patients in our cohort, 44%
had a history of atopy (allergic rhinitis and/or asthma). Multivariate logistic analysis revealed that a preexisting his-
tory of atopy was highly predictive of idiopathic pulmonary complications (P = .0001, odds ratio = 21, CI 3.6-125).
Our experience shows that HDT followed by AHCT results in durable remissions in two thirds of pediatric
patients with refractory and relapsed Hodgkin’s disease, and a history of atopy is associated with post-AHCT pul-
monary complications.
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(AHCT). Although durable remissions have been reported
[3-5], there remain concerns regarding toxicities encoun-
tered during and after AHCT.
Pulmonary injury is one of the major toxicities of HDT.
Nonbacterial, nonfungal interstitial pneumonitis may occur
in up to 15% and diffuse alveolar hemorrhage (DAH) syn-
drome in approximately 20% of pediatric patients undergo-
ing HDT [6,7]. Up to 10% of patients undergoing HDT
die of pulmonary complications during initial hospitaliza-
tion [8]. Factors thought to predispose to the development
of post-HDT pulmonary complications include prior chest
irradiation [9], prior bleomycin therapy [10], and carmustine
(BCNU)/chloroethylcyclohexylnitrosurea (CCNU) [11].
We report the outcome of 34 pediatric patients with
progressive or relapsed Hodgkin’s disease treated with
HDT/AHCT. Prior chemo/radiotherapy, disease status, atopic
status, and posttransplantation complications were assessed.
We observed a signiﬁcantly increased rate of pulmonary com-
plications in patients with a prior history of atopic symptoms.
PATIENTS AND METHODS
Study Design
We conducted a retrospective chart review of 34 consecu-
tive pediatric Hodgkin’s disease patients (age range, 7-21 years;
median, 17 years) with either primary refractory or relapsed
disease. Patients were entered into 3 consecutive transplanta-
tion protocols at Stanford University Hospital and Lucile
Salter-Packard Children’s Hospital at Stanford, CA between
September 1989 and September 1998. All clinical research
protocols were approved by the institutional review board.
Definitions
Patients were considered to have primary refractory dis-
ease if progression occurred during the initial planned treat-
ment or if they had only a partial or transient response (last-
ing <60 days) to planned therapy [12]. Patients who had no
evidence of tumor by clinical, biochemical, or radiologic
evaluation by day 30 were classiﬁed as having a CR [13]. In
addition, patients who achieved >80% tumor reduction in
2 tumor dimensions but had persistent radiographic abnor-
malities that did not change for >1 year were also considered
to have a CR [14]. Patients with >50% tumor reduction
without progression of existing disease or development of
new lesions over 30 days were classiﬁed as having a partial
response (PR) [13]. Bulky disease was deﬁned as cross-sectional
measurement of >5 cm or mediastinal disease occupying
more than one third of the intrathoracic diameter on
upright chest radiograph. Patients were considered to have
stable disease if there was no change in tumor dimensions
over the stated time course. Patients were classiﬁed as atopic
if symptoms of allergic rhinitis (seasonal or perennial)
and/or asthma were present before transplantation.
Patient Characteristics
Patient characteristics are listed in Table 1. All
patients had previously received conventional multiagent
chemotherapy with a median exposure to 6 drugs and 1
regimen before cytoreduction and HDT: 15 patients had
previously received MOPP/ABV(D) [mechlorethamine,
vincristine, prednisone, procarbazine/doxorubicin,
bleomycin, vinblastine, (dacarbazine)] or COPP/ABV(D)
[cyclophosphamide, vincristine, prednisone, procar-
bazine/ABV(D)]; 4 patients had ABV(D) only; 2 patients
had MOPP only; and the remainder had VEPA (vinblas-
tine, etoposide, prednisone, doxorubicin), VAMP (vin-
blastine, doxorubicin, methotrexate, prednisone), Stan-
Table 1. Characteristics of Pediatric Patients With Relapsed Hodgkin’s
Disease Who Underwent Subsequent HDT/AHCT*
No. of patients 34
No. of males/females 21/13
Median age in years at diagnosis (range) 15 (5-18)
Median age in years at transplantation (range) 17 (7-21)
Characteristics at diagnosis
Histology
Nodular sclerosing 33
Lymphocyte predominant 1
Disease stage at diagnosis
I/II 12
III/IV 22
Initial presentation
B symptoms 22
Presence of bulky disease 26
Presence of mediastinal mass 21
Presence of extranodal disease 18
Median duration in months of initial remission (range) 15.2 (3-44)
Chemotherapy prior to cytoreduction
Conventional chemotherapy 34
Median number of drugs (range) 6 (3-10)
Median number of regimens (range) 1 (1-2)
Bleomycin 23
Disease status prior to cytoreduction 34
Primary refractory disease 7
Treated with cytoreduction regimen 6
First relapse 23
Treated with cytoreduction regimen 20
Second relapse 4
Treated with cytoreduction regimen 4
Presentation at HDT/ABMT 31
Presence of bulky disease 6
Presence of mediastinal mass 14
Presence of extranodal disease 7
Thoracic RT 33
Pretransplantation thoracic RT 24
Pretransplantation RT within 6 months before 4 
HDT/AHCT
Transplantation-associated RT (ie, FTBI during HDT) 6
Posttransplantation thoracic RT† 9
Peritransplantation thoracic RT†‡ 18
*HDT indicates high-dose therapy; ABMT, autologous bone mar-
row transplantation; RT, radiotherapy; AHCT, autologous hemato-
poietic cell transplantation; FTBI, fractionated total body irradiation.
†Two patients received thoracic RT after they recovered from a
chloroethylcyclohexylnitrosurea (CCNU)-associated diffuse lung injury
syndrome; therefore, this RT was not included in the analysis of pre-
dictors of pulmonary toxicity.
‡Peritransplantation thoracic RT includes all patients who received
pretransplantation RT within 6 months before HDT/AHCT, trans-
plantation-associated RT (ie, FTBI during HDT), or posttransplanta-
tion thoracic RT. One patient received both pretransplantation and
transplantation-associated RT.
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ford V (mechlorethamine, doxorubicin, vinblastine, pred-
nisone, vincristine, bleomycin, etoposide), or other simi-
lar drug combinations. Twenty-three patients had previ-
ous bleomycin exposure, of whom 1 patient developed
bleomycin-induced restrictive lung disease before HDT
and transplantation.
Assignment of disease status was based on clinical presen-
tation before administration of pretransplantation cytoreduc-
tion (“de-bulking”) chemotherapy (Table 1). Seven patients
had primary refractory disease, of whom 6 patients were
treated with cytoreduction therapy. Twenty-three patients
were in ﬁrst relapse, of whom 20 patients were treated with
cytoreduction. Four patients were in second relapse, and all
underwent cytoreduction. Cytoreductive chemotherapy con-
sisted of MOPP in 13 patients, DHAP (dexamethasone, cis-
platin, cytarabine) in 11 patients, and Stanford V and other
similar regimens in the remaining patients. Two of these
patients also received involved ﬁeld radiotherapy (RT).
Immediately before HDT/AHCT, 17 patients were in
remission, 12 patients had persistent stable disease, and
2 patients had progression of disease after cytoreduction
therapy. The status of 3 patients before AHCT was unclear.
Of the 14 patients with persistent disease, 14 patients had a
mediastinal mass, 7 patients had extranodal disease, and
6 patients had bulky disease. All but 6 patients had pul-
monary function testing (spirometry and carbon monoxide
diffusion capacity [DLCO] determination) before initiation
of the preparative regimen.
Thoracic RT
The details of thoracic RT are depicted in Tables 1 and 2.
All but 1 patient received RT to the thorax. Twenty-four
patients received pretransplantation thoracic RT, of whom
4 patients received thoracic RT within 6 months before
HDT/AHCT. Six patients received fractionated total body
irradiation (FTBI) during HDT, which included RT to the
thorax. Nine patients received posttransplantation thoracic
RT. Eighteen patients received peritransplantation radiation
(ie, within 6 months before transplantation, during HDT, or
after transplantation). One patient in the peritransplantation
group received thoracic RT 2 months before transplanta-
tion, as well as FTBI.
Posttransplantation thoracic RT was administered 20 to
40 days post-AHCT except in 2 patients with pulmonary
complications in whom RT was delayed (72 and 125 days
after transplantation). These 2 patients received posttrans-
plantation RT after the development of diffuse lung injury
syndrome; thus, this RT was not included when analyzing
predictors of lung injury and is not depicted in Table 2.
For patients receiving thoracic and/or pulmonary radia-
tion, radiation doses were calculated to the central axis for
thoracic radiation (generally the mediastinum) and the mid-
plane of the lung for pulmonary radiation and reported as a
midplane pulmonary dose in centigray (cGy) (Table 2).
Marrow and Peripheral Blood Cell Harvest,
Cryopreservation, and Reinfusion
Bone marrow biopsies were documented to be histologi-
cally normal within 1 month of the collection of hemato-
poietic cells. Hodgkin’s disease was detected in the bone
marrow of 3 patients at diagnosis; all 3 patients were in a
bone marrow remission at the time of harvest. Twenty
patients received peripheral blood stem cells; 11 patients
received both mobilized peripheral blood stem cells and
harvested bone marrow cells; and 3 patients received only
bone marrow grafts.
HDT Regimen
Patients received either BCNU (n = 17; 10-15 mg/kg;
day –6), CCNU (n = 11; 6 mg/kg, day –6), or FTBI (n = 6;
day –8 through day –5). FTBI was administered as
1200 cGy photon radiation to the midplane in ten 120 cGy
fractions using lung blocks with 600 cGy electron boosts to
the anterior and posterior ribs in two 300 cGy fractions. All
patients received etoposide (60 mg/kg; day –4) and cyclo-
phosphamide (100 mg/kg; day –2). Bone marrow was
thawed and infused on day 0. Drug dose calculations were
based on actual or adjusted ideal body weight.
Supportive Care
Patients were hospitalized in isolation rooms. Prophy-
lactic antibiotics consisted of trimethoprim/sulfamethoxa-
zole. Blood products were irradiated and given to maintain a
hemoglobin level >10 mg/dL and a platelet count >10 
103/µL or for bleeding. Empiric broad-spectrum antibiotics,
antifungal therapy, and parenteral hyperalimentation were
used as clinically indicated.
Evaluation
Tumor restaging studies were performed at day 100
post-AHCT. Routine tumor staging studies were repeated
every 3 to 6 months for 2 years and then yearly, unless
symptoms of disease recurred.
Pulmonary Toxicity
Patients were classified as having either infectious or
noninfectious lung injury. Patients with infectious lung
injury underwent bronchoalveolar lavage (BAL) and were
found to have infection by various diagnostic methods (cul-
ture, antibody studies, etc.). Patients with noninfectious
lung injury included those diagnosed with acute alveolitis,
diffuse alveolar hemorrhage, acute respiratory distress syn-
drome (ARDS), delayed interstitial pneumonia, and bron-
chiolitis obliterans based on a variety of observations,
including clinical assessment, pulmonary function tests,
radiologic studies, bronchoscopy/open lung biopsy (with
microbiologic and pathologic studies), and autopsy. These
patients were grouped and collectively referred to as having
a “diffuse idiopathic lung injury syndrome.” Of these
15 patients, 10 underwent an invasive study (BAL, open
biopsy, or autopsy). Four of the 5 patients who did not
undergo invasive study had delayed interstitial pneumonia
with typical clinical symptoms (cough, dyspnea, tachypnea)
and chest radiographs (diffuse interstitial inﬁltrates), abnor-
mal pulmonary function tests (restrictive pattern), and a
prompt response to steroid therapy. The other patient with-
out an invasive diagnostic study had ARDS/multiorgan fail-
ure with multiple negative blood cultures.
Statistical Methods
The end points considered in the data analysis were
overall survival, disease-free survival, and diffuse lung
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injury syndromes. All data were calculated from the time
of AHCT (day 0).
Variables analyzed included presence of B symptoms
(systemic symptoms such as drenching night sweats and
weight loss), bulky disease, mediastinal mass, extranodal dis-
ease, and primary induction failure. These variables were
assessed at the time of diagnosis and at the time of relapse.
In addition, presence of bulky disease, mediastinal mass, and
extranodal disease were assessed immediately before HDT.
The following variables were considered in univariate
and multivariate analysis as predictors of pulmonary complica-
tions: atopy; pre-AHCT thoracic irradiation; thoracic irradia-
tion 6 months before AHCT; post-AHCT thoracic irradiation;
peri-AHCT irradiation (irradiation 6 months before and/or
after AHCT); previous bleomycin therapy; HDT regimen;
and pre-AHCT pulmonary function tests, including forced
vital capacity (FVC), forced expiratory volume (FEV1), and
DLCO.
The influence of the categorical factors on response
(overall survival and disease-free survival) was estimated by
Cox proportional hazard regression [15]. All variables found
to have a P value < .10 in univariate analyses were included
in stepwise multivariate analyses. The inﬂuence of categori-
cal factors on the development of pulmonary toxicity was
estimated by logistic regression. Overall survival rate, dis-
ease-free survival rate, and time to pulmonary complication
were estimated using the Kaplan-Meier method [16]. The
Mann-Whitney test was used for comparing groups when
variables were continuous [17], and Pearson’s chi-square test
was used when factors were dichotomous.
RESULTS
Hematologic Engraftment
The median time to achieve an absolute neutrophil
count (ANC) > 0.5  103/µL was 10 days (range, 1-31 days).
Three patients died after neutrophil engraftment but before
platelet recovery >20  103/µL. The median time to achieve
a platelet count >20  103/µL was 15 days (range, 6-38 days)
in 30 assessable patients, whereas the median time to achieve
a platelet count >100 103/µL was 30 days (range, 12-
548 days) in 25 assessable patients. One patient reached an
ANC >0.5  103/µL by day 14 and platelet >20  103/µL by
day 13, but graft failure ensued with ANC dropping to 0 on
day 35 and platelets to 6  103/µL on day 23. This patient
eventually recovered without supplemental hematopoietic
cell reinfusion, achieving an ANC >1  103/µL on day 64,
and platelet support was discontinued 7 months post-AHCT.
Nonhematologic Toxicity
Fifteen patients had documented infections within the
ﬁrst 30 days after AHCT, and 16 patients had documented
infections between 1 and 12 months after AHCT (Table 2).
Three patients developed severe liver dysfunction character-
ized by hyperbilirubinemia (total bilirubin values >5 times
normal), but without the pain or weight gain consistent with
veno-occlusive disease. Milder, reversible abnormalities of
liver function tests (total bilirubin 2 to 5 times normal) were
observed in 4 other patients, again without other evidence
of hepatic veno-oclusive disease.
Pulmonary Toxicity
Pulmonary toxicity data are reported in Table 2. Seven-
teen patients developed a pulmonary complication after
transplantation, resulting in 5 deaths. Two patients devel-
oped infectious nondiffuse pulmonary disease with radi-
ographs indicating focal involvement (cytomegalovirus
pneumonia and necrotizing Legionella pneumonia). Fifteen
patients (44%) developed an idiopathic diffuse lung injury
syndrome. Of note, 12 of these 15 patients (80%) reported a
history of atopy before HDT/AHCT (Table 2). Using uni-
variate logistic analysis, atopy predicted pulmonary compli-
cations (P = .0001; odds ratio = 15, 95% conﬁdence interval
[CI] 2.8-80) (Figure 1).
Of the 15 patients with idiopathic diffuse lung injury
syndromes, 6 developed the pulmonary complication acutely
(days 0-30), including 2 patients with ARDS, 2 with acute
alveolitis, and 2 with DAH. Both patients with ARDS devel-
oped respiratory distress on day 7 and had concomitant sys-
temic inflammatory response syndrome (SIRS). Patients
with alveolitis and DAH developed respiratory distress
between days 11 and 14. Five of these 6 patients with acute
pulmonary disease (83%) had a history of atopy. Three
patients—all of whom had reported a history of asthma
before transplantation—died of respiratory failure. The
remaining patient recovered while on high-dose steroid
therapy and extended steroid taper.
Of the 15 patients with idiopathic diffuse lung injury
syndromes, 9 had a delayed onset of the pulmonary compli-
cation (after day 30), including 8 patients with interstitial
pneumonitis (IP) and 1 patient with bronchiolitis obliterans.
Patients developed this delayed pulmonary disease at a
median time of 44 days (range, 29-50 days) posttransplanta-
tion and typically presented with cough, dyspnea, and
tachypnea. Their chest examination was either unremarkable
or notable for bilateral diffuse rales. Arterial blood gasses fre-
quently indicated hypoxia and hypocapnia. Patients who
underwent pulmonary function testing exhibited both
Figure 1. Incidence of pulmonary complications in the days following
autologous hematopoietic cell transplantation (AHCT) as a function of
atopic versus nonatopic status. , atopy (n = 15); ,
nonatopy (n = 19).
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restrictive defects and reduced DLCO. Radiologic studies
revealed a diffuse interstitial inﬁltrate in all patients. All but
2 cases of delayed pulmonary toxicity occurred within the
atopic group. All were treated promptly with corticosteroids
followed by extended taper. Two patients developed recur-
rent IP during steroid taper. Three patients showed chronic
restrictive defects on pulmonary function tests but maintained
a 100% performance on minimal doses of corticosteroid
medication 3 years later. One patient developed spontaneous
apical pneumothorax on 3 occasions up to 3 years after full
recovery from IP. The remaining patients recovered fully or
with only minor restrictive defects.
One patient developed a self-limited interstitial pulmonary
process that was incidentally discovered by chest radiograph.
This patient was without symptoms and did not require steroid
therapy, and thus was not identiﬁed as having IP.
Status Post-HDT/HCT
As Table 3 shows, 5 treatment-related deaths occurred.
Four atopic patients died; 3 patients died of pulmonary toxi-
city <40 days post-AHCT and 1 of an undeﬁned viral syn-
drome 7.5 months post-AHCT. One nonatopic patient died
from Legionella pneumonia 2 months post-AHCT. Twenty-
eight patients achieved CR, of whom 8 relapsed after
achieving CR. Of these patients, 3 relapsed at <12 months
and 5 patients relapsed at >12 months. One patient achieved
PR and relapsed at 3 months post-AHCT.
Disease-Free Survival 
Sixty-seven percent (95% CI, 47%-87%) of patients are
projected to be alive and disease-free at 5 years (Figure 2A).
Predictors of disease-free survival by univariate analysis
were the absence of the following: B symptoms at first
relapse (P = .07), extranodal disease at ﬁrst relapse (P = .03),
bulky disease at AHCT (P = .03), and mediastinal mass at
AHCT (P = .02). Using multivariate analysis, extranodal dis-
ease at relapse (P = .005, risk ratio = 20.4, 95% CI 2.2-
192.5) and bulky disease at AHCT (P = .008, risk ratio =
27.3, 95% CI 2.7-270.6) remained the only signiﬁcant pre-
dictors of disease-free survival.
Overall Survival
Seventy-six percent (95% CI, 62%-90%) of patients are
projected to be alive at 5 years (Figure 2B). Using univariate
analysis, the predictors of survival were absence of B symp-
toms at diagnosis (P = .0005) and at relapse (P = .04),
absence of extranodal disease at relapse (P = .03), and
absence of primary refractory disease (P = .02). By multivari-
ate analysis, only absence of extranodal disease at relapse
was a signiﬁcant predictor of survival (P = .04, risk ratio =
4.3, 95% CI 1.1-16.8).
DISCUSSION
In this series, a 5-year disease-free survival rate of 67%
following HDT/AHCT in children with primary refractory
and relapsed Hodgkin’s disease compares favorably with
other recently published data. Using similar preparatory
regimens and candidates, the 5-year disease-free survival
rate has recently been reported to be 31% to 62% [3-5]. As
in the other series, we also observed a small number of
patients relapsing late after transplantation, suggesting the
need for long-term follow-up.
Our incidence of idiopathic diffuse lung injury (44%) is
substantially higher than the incidence of 12% to 13%
reported among pediatric and adult Hodgkin’s disease
patients receiving similar regimens [5,14,18]. It is also
higher than the 18% incidence of similar pulmonary com-
plications in children with non-Hodgkin’s lymphoma
treated with a high-dose regimen consisting of cytarabine,
6-thioguanine, BCNU, and cyclophosphamide [19]. The
reason for this increased incidence of pulmonary toxicity is
not clear and may be related to the fact that we conducted
an extensive review of the outpatient course where we com-
bined both acute and delayed diffuse lung injury syndromes,
whereas the previous studies considered these separately.
Previous studies identified prior or transplantation-
associated radiation to the thorax [7,14,18], prior lung dis-
ease, prior therapy with bleomycin [10], and BCNU/
CCNU [11] as risk factors for the development of diffuse
lung injury syndromes. In our cohort, the incidence of such
complications in patients who received pre-HDT thoracic
RT was not signiﬁcantly different than in patients without a
history of thoracic radiation (P = .23). Recent radiation
(within 6 months of AHCT, including FTBI) and post-
AHCT radiation were also not correlated with the develop-
ment of pulmonary disease (P = .8 and P = .75, respectively).
In addition, peritransplantation radiation (recent and post-
Table 3. 
Status of Pediatric Patients With Relapsed Hodgkin’s Disease Who Underwent Subsequent HDT/AHCT*
Total Patients (n = 34) Atopic Patients (n = 15) Nonatopic Patients (n = 19)
Death due to transplantation-related complication 5 4 1
Early toxic death 3 3
Late toxic death 2 1 1
Complete responders 28 11 17
CR with relapse <12 mo 3 0 3
CR with relapse >12 mo 5 2 3
CR with no disease relapse† 20 9 11
Partial responders with disease relapse <12 mo 1 0 1
*HDT indicates high-dose therapy; AHCT, autologous hematopoietic cell transplantation; CR, complete response.
†One patient developed acute lymphocytic leukemia 1 year posttransplantation.
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AHCT was grouped) did not correlate with the develop-
ment of diffuse lung injury syndromes (P = .88). Prior
bleomycin was also not correlated with pulmonary compli-
cations (P = .091). Abnormalities in pretransplantation pul-
monary function tests (FVC, FEV1, and DLCO) also did not
correlate with pulmonary complications (P = .19, P = .45,
and P = .89, respectively). Furthermore, the incidence of
pulmonary complications was similar between the patients
who received BCNU, CCNU, or FTBI.
However, we found that among 15 patients with
pulmonary complications, 80% had an atopic diathesis
(Table 2). Furthermore, all 3 patients who died of pul-
monary failure had a documented history of childhood
asthma and allergic rhinitis. Atopy was highly predictive of
idiopathic diffuse lung injury syndromes (P = .0001, odds
ratio = 21, 95% CI 3.6-125). Of interest, a previous study of
143 Hodgkin’s disease patients revealed that pretransplanta-
tion bronchial airway inﬂammation (by BAL) was predictive
of posttransplantation diffuse lung injury [20]. Moreover,
cryopreserved lung tissue from 12 patients with posttrans-
plantation interstitial pneumonitis demonstrated increased
expression of TH2 cytokines [21]. The TH2 cytokine proﬁle
is well established as “driving” mucosal and bronchial airway
inﬂammation associated with the atopic diathesis.
Hodgkin’s disease is characterized by the combination of
Reed-Sternberg (RS) cells and a prominent inflammatory
cell inﬁltrate. RS cells have recently been shown to produce
interleukin (IL)-13 and IL-5 (TH2 cytokines) in large quan-
tities relative to their production of other cytokines [22].
IL-13 and IL-5 are also TH2 cytokines known to drive the
effector functions of the allergic immune responses, includ-
ing eosinophil, mast cell, and basophil trafﬁcking, activation,
and survival [23-33]. Increased production of IL-13 (as well
as IL-5) is well documented in asthma [34] and allergic
rhinitis [35]. Furthermore, mice transgenic for IL-13 have
increased pulmonary expression of eotaxin and develop pul-
monary inflammation and subepithelial fibrosis [24]. The
ability of IL-13 to selectively induce the respiratory produc-
tion of eotaxin may have important implications in the traf-
ficking of inflammatory cells to the respiratory system in
Hodgkin’s disease patients.
Patients with atopy may have a heightened sensitivity to
the TH2 cytokines that is worsened by concomitant
Hodgkin’s disease. Given this, atopic patients may have a
predisposition to the trafﬁcking of inﬂammatory cells to the
lungs, increasing the lungs’ susceptibility to inflammatory
lung conditions after HDT/AHCT. Thus, the atopic symp-
toms of TH2 polarization may predict the development of
posttransplantation lung pathology. The role of atopy and
the pathogenesis of chemotherapy/RT–induced lung disease
has not been previously described.
Of note, granulocyte colony-stimulating factor (G-CSF)
is routinely administered post-AHCT. One patient in our
series refused G-CSF because of prior intolerance. Interest-
ingly, she was the only asthmatic patient in this study who
did not develop a pulmonary complication, nor did her fol-
low-up chest radiographs indicate pulmonary infiltrates.
Prior case reports suggest that treatment with G-CSF may
increase a patient’s risk for developing interstitial pneumoni-
tis [36-38]. There may be a synergistic effect of IL-13, G-CSF,
and atopic host factors in the development of posttransplan-
tation diffuse lung injury syndromes.
Our experience conﬁrms that progressive and relapsed
pediatric Hodgkin’s disease patients can be successfully
treated with HDT and AHCT. However, pediatric Hodgkin’s
disease patients with atopic symptoms have a significantly
higher rate of idiopathic diffuse lung injury syndromes. This
observation may have important implications regarding the
management of atopic patients with Hodgkin’s disease
undergoing HDT and AHCT.
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